rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Eledon Pharmaceuticals, Inc.

ELDN · Nasdaq

Health CareBiotechnologyNot moving yet

ELDN stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 36.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 8
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
154 (+39)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders154+39 on the quarter
New · exited50 · 10
Reported value$184.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BVF INCunchanged · filed 14 Aug 20266,293,282$24.8M00.0%
BlackRock, Inc.added · filed 7 Aug 20265,123,842$20.2M+741,597+16.9%
Defilade Capital Management, L.P.reduced · filed 14 Aug 20263,525,338$13.9M-38,789−1.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,417,223$13.5M+124,089+3.8%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20262,510,308$9.9M+2,140,218+578.3%
Ensign Peak Advisors, Increduced · filed 14 Aug 20262,101,224$8.3M-363,695−14.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,956,601$7.7M+164,818+9.2%
Catalio Capital Management, LPadded · filed 14 Aug 20261,695,071$6.7M+55,255+3.4%
STATE STREET CORPadded · filed 7 Aug 20261,621,969$6.4M+467,298+40.5%
Zimmer Partners, LPreduced · filed 14 Aug 20261,596,599$6.3M-278,401−14.8%
31 Mar 2023 – 30 Jun 2026
2788149Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David-Alexandre C. Gros Company insiderChief Executive Officer · last 31 Jul 20263 · 0
Steven Perrin Company insiderPresident · last 31 Jul 20261 · 0
Allan Kirk Company insiderDirector · last 10 Jan 20260 · 0
James A. Robinson Jr. Company insiderDirector · last 10 Jan 20260 · 0
Jan Hillson Company insiderDirector · last 10 Jan 20260 · 0
John S. McBride Company insiderDirector · last 10 Jan 20260 · 4
June Lee Company insiderDirector · last 10 Jan 20260 · 0
Keith Katkin Company insiderDirector · last 10 Jan 20260 · 0
Bryan E. Smith Company insiderGeneral Counsel, Corporate Sec · last 10 Jan 20250 · 0
Paul Sean Little Company insiderChief Financial Officer · last 10 Jan 20251 · 0
Biotechnology Value Fund Ii Lp Company insiderOther · last 29 Oct 20240 · 0
Bvf Inc/il Company insider10% owner · last 9 May 20241 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 13 Mar 20260.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$22.8M

Analyst forecasts

No analyst forecasts yet.